Detalhe da pesquisa
1.
Innovation and Missed Opportunities in Internal Medicine Undergraduate Education During COVID-19: Results from a National Survey.
J Gen Intern Med
; 37(9): 2149-2155, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35710667
2.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 95(12): 1457-1465, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32777116
3.
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Cancer
; 124(2): 325-334, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29211308
4.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Haematologica
; 103(6): 982-987, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567781
5.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Lancet Oncol
; 18(10): 1317-1326, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844816
6.
Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
Clin Lymphoma Myeloma
; 7(4): 319-22, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17324342